Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

ARIX BIOSCIENCE PLC Regulatory Filings 2019

Nov 7, 2019

4968_rns_2019-11-07_9df2d0fa-e69a-4b63-b7b6-1da0478b7030.html

Regulatory Filings

Open in viewer

Opens in your device viewer

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

Arix Bioscience Plc - Change of Broker

PR Newswire

London, November 7

Arix Bioscience plc

Change of Broker

LONDON, 07 November, 2019: Arix Bioscience plc (“Arix”, LSE: ARIX) a global venture capital company focused on investing in and building breakthrough biotech companies, today announces that it has appointed Peel Hunt LLP as joint corporate broker, with immediate effect, alongside its existing corporate broker Jefferies International Limited.

Enquiries

For more information on Arix, please contact:

Arix Bioscience plc

Charlotte Parry, Head of Investor Relations

+44 (0)20 7290 1072

[email protected]  

Optimum Strategic Communications

Mary Clark, Supriya Mathur

+44 (0)203 714 1787

[email protected]

About Arix Bioscience plc

Arix Bioscience plc is a global venture capital company focused on investing in and building breakthrough biotech companies around cutting edge advances in life sciences.

We collaborate with exceptional entrepreneurs and provide the capital, expertise and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors.

Arix Bioscience plc is listed on the Main Market of the London Stock Exchange. For further information, please visit www.arixbioscience.com